Ranbaxy Laboratories announced that its new anti-malarial combination drug is now undergoing final stage of development. In its press-release, the company said that the drug is targeted at patients in developing countries with the aim of significantly improving upon the conventional options available for the treatment of P falciparum malaria.
The company has commenced phase-III clinical trials for its new anti-malaria combination drug, a combination of arterolane maleate and piperaquine phosphate in India, Bangladesh and Thailand. Arterolane maleate and piperaquine phosphate is made from synthetic intermediates and hence easier to manufacture with better predictability and reliability of supplies. The drug is being developed as a once-a-day therapy for three days compared to existing therapy which requires an adult to consume 24 tablets over three days. Ranbaxy Labs’ chairman, CEO and MD, Malvinder Singh, said, “Our new anti-malaria drug, likely the first new chemical entity (NCE) from India, will benefit patients immensely and provide a more potent solution to developing nations where Malaria is endemic.”